Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Glucophage XR (Indonesia vs France) in Healthy Subjects
NCT03583385Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Aug 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Merck KGaA. Primary endpoints: Maximum Observed Plasma Concentration at 32 hours and Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration at 32 hours. Started Aug 2018; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03583385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03583385.